Sulbactam. New treatment options for critically ill patients.

The main effect of the drug SULBACTAM-GPHC® is to protect against the destruction of a number of beta-lactam antibiotics (for example, cephalosporins, penicillins) by enzymes - beta-lactamases. Beta-lactamases are substances synthesized by pathogenic bacteria that destroy antibiotics and make them inactive (ineffective), which causes the development of resistance to antibiotic therapy, including multiple ones. Multiple drug resistance leads to the development of extremely aggressive pathogens that cause nosocomial infections, which lead to severe consequences for both patients and the healthcare system as a whole.

The advantage of SULBACTAM-GPHC® is the possibility of making a combination with an antibiotic within the wide permitted limits for the selection of effective personalized antibacterial therapy. Also, the use of LP SULBACTAM-GPHC® allows you to reduce the cost of therapy, in comparison with ready-made fixed combinations, which in turn leads to optimization of the costs of medical institutions.

For more effective prevention and treatment of hospital infection and its complications, health experts in the round table format discuss new possibilities of antibacterial therapy for patients in critical conditions, taking into account new possibilities of combining antibiotics with a beta-lactamase inhibitor.

The structure of the round table:

— "Sulbactam and other "classic" beta lactamase inhibitors: "basic" information"

Speaker: Andrey V. Dehnich — Candidate of Medical Sciences, Deputy Director for Scientific Work of the Research Institute of Antimicrobial Chemotherapy of the Smolensk State Medical University of the Ministry of Health of the Russian Federation (Russia, Smolensk);

— "Sulbaktam. Clinical application experience and practical advice"

Speaker: Konstantin Nikolaevich Zolotukhin — Candidate of Medical Sciences, Chief Freelance Anesthesiologist-Resuscitator of the Ministry of Health of the Republic of Bashkortostan, Head of the Department of Anesthesiology and Intensive Care No. 1 of the G.G. Kuvatov RCB (Russia, Ufa);

— "Sulbaktam. Where does an intensive care doctor need him?"

Speaker: Vladimir V. Kulabukhov - President of the Russian Sepsis Forum, leading researcher at the State Medical Institution "N.V. Sklifosovsky Research Institute of Emergency Medicine of the Moscow City Department of Health" (Russia, Moscow);